1. Home
  2. CPF vs JANX Comparison

CPF vs JANX Comparison

Compare CPF & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Pacific Financial Corp New

CPF

Central Pacific Financial Corp New

HOLD

Current Price

$37.43

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$17.39

Market Cap

975.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPF
JANX
Founded
1954
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
975.7M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
CPF
JANX
Price
$37.43
$17.39
Analyst Decision
Buy
Buy
Analyst Count
2
13
Target Price
$37.00
$47.00
AVG Volume (30 Days)
132.4K
670.6K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
3.39%
N/A
EPS Growth
45.18
N/A
EPS
1.58
N/A
Revenue
$51,817,000.00
$10,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.62
N/A
P/E Ratio
$23.73
N/A
Revenue Growth
33.81
N/A
52 Week Low
$27.40
$12.12
52 Week High
$40.99
$35.34

Technical Indicators

Market Signals
Indicator
CPF
JANX
Relative Strength Index (RSI) 39.53 63.92
Support Level $33.33 $13.13
Resistance Level $39.59 $30.47
Average True Range (ATR) 0.83 0.58
MACD -0.28 0.12
Stochastic Oscillator 17.37 83.58

Price Performance

Historical Comparison
CPF
JANX

About CPF Central Pacific Financial Corp New

Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: